AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca PLC closed 23.78% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...